Merck KGaA (FRA:MRK) has been assigned a €123.00 ($146.43) target price by stock analysts at Citigroup Inc. in a report released on Monday. The firm currently has a “buy” rating on the healthcare company’s stock.

MRK has been the subject of a number of other reports. Morgan Stanley set a €103.00 ($122.62) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Monday, May 29th. Warburg Research set a €116.00 ($138.10) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Monday, May 29th. DZ Bank AG reissued a “neutral” rating on shares of Merck KGaA in a report on Monday, May 29th. Berenberg Bank set a €106.00 ($126.19) price objective on Merck KGaA and gave the stock a “neutral” rating in a report on Monday, May 29th. Finally, Kepler Capital Markets set a €128.00 ($152.38) price objective on Merck KGaA and gave the stock a “buy” rating in a report on Thursday, June 1st. Thirteen equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of €108.38 ($129.02).

Merck KGaA (FRA MRK) opened at 97.70 on Monday. The firm has a 50 day moving average price of €93.46 and a 200 day moving average price of €102.32. Merck KGaA has a 52 week low of €89.00 and a 52 week high of €115.00. The stock has a market capitalization of €42.48 billion and a P/E ratio of 25.47.

WARNING: “Merck KGaA (MRK) Given a €123.00 Price Target at Citigroup Inc.” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/09/25/merck-kgaa-mrk-given-a-123-00-price-target-at-citigroup-inc-2.html.

About Merck KGaA

.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.